Send the following on WhatsApp
Continue to ChatLong-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial - https://avesis.hacettepe.edu.tr/publication/details/cfec1dd1-d206-4dca-b02b-c1c95b4f493d/long-term-efficacy-and-safety-of-sapropterin-in-patients-who-initiated-sapropterin-at-4-years-of-age-with-phenylketonuria-results-of-the-3-year-extension-of-the-spark-open-label-multicentre-randomised-phase-iiib-trial